Although the biliary phenotype of CFLD could plausibly respond to CFTR modulation, the vascular subtype, characterized by non-cirrhotic portal hypertension, has an uncertain pathogenesis and its response to ETI is unknown. The gene discussed is CFTR; the disease is liver disorder.